logo
Products
Technologies
Applications
Services
Resources
Selection Guides
About
PE Mouse Anti-human HLA-A2 Antibody
BB7.2, monoclonal
HLA class I histocompatibility antigen, A α chain is a 47 kDa transmembrane protein that can be expressed in the integral component of lumenal side of endoplasmic reticulum membrane, cell surface and recycling endosome membrane of cells. In Homo sapiens, HLA class I histocompatibility antigen, A α chain has been found to be involved in organismal processes, namely, T cell mediated cytotoxicity directed against tumor cell target, defense response to Gram-positive bacterium and CD8-positive, α-beta T cell activation. Sequencing of HLA class I histocompatibility antigen, A α chain has exemplified it contains 3 conserved structural units: extracellular, Ig-like C1-type and cytoplasmic domain. It is the subject of intensive research due to the fact that it plays a role in the antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent, TAP-dependent and type I interferon signaling pathway. Moreover, HLA class I histocompatibility antigen, A α chain recognizes signaling receptor, TAP complex and T cell receptor. It is a positive regulator of interferon-γ production, T cell mediated cytotoxicity and CD8-, α-beta T cell proliferation. It takes part in processes such as immune response.
General packaging for catalog V103885. Actual shipped packaging may vary.
General packaging for catalog V103885. Actual shipped packaging may vary.
CatalogSize
Price
Quantity
V103885100 tests
Price
 
Antibody properties

CloneBB7.2
Hostmouse
Reactivityhuman
ApplicationFC (QC TESTED)
Storage, safety and handling

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on September 20, 2025